Valuation: Perspective Therapeutics, Inc.

Market Cap 368M 317M 298M 271M 510M 35.14B 517M 3.49B 1.37B 17.61B 1.38B 1.35B 58.57B P/E 2026 *
-3.14x
P/E 2027 * -2.91x
Enterprise Value 201M 174M 163M 148M 279M 19.22B 283M 1.91B 748M 9.63B 755M 738M 32.03B EV / Sales 2026 *
599x
EV / Sales 2027 * 345x
Free-Float
89.2%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week+7.33%
Current month+10.65%
1 month+7.69%
3 months-16.36%
6 months-33.61%
Current year+17.09%
1 week 3.03
Extreme 3.03
3.3
1 month 2.69
Extreme 2.69
3.3
Current year 2.25
Extreme 2.25
6.16
1 year 1.96
Extreme 1.955
6.16
3 years 1.6
Extreme 1.6
19.05
5 years 1.6
Extreme 1.6
19.05
10 years 1.6
Extreme 1.6
28.1
Manager TitleAgeSince
Chief Executive Officer 54 04/02/2023
Director of Finance/CFO 59 03/09/2025
Chief Tech/Sci/R&D Officer - 07/07/2026
Director TitleAgeSince
Director/Board Member 54 04/02/2023
Chairman 63 02/02/2023
Director/Board Member 60 04/02/2023
Date Insider Type Main position Quantity % Market Cap.
02/03/26 Free

Director

50,000 0.0439%
13/11/25 Buy

Controller/Auditor

11,000 0.0148%
12/11/25 Buy

Director

9,498 0.0128%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%+7.33%-10.80%-16.62% 368M
-0.28%-1.56%+1.91%+20.03% 48.84B
+4.07%+2.43%+483.70%+623.80% 45.44B
+4.33%+0.98%+12.80%+88.53% 41.22B
+1.94%-0.31%+26.24%+12.62% 39.71B
-0.50%0.00%+20.60%+60.49% 32.6B
+0.10%-3.22% - - 16.25B
+3.22%-0.88%+30.42%+135.47% 16.67B
-0.69%-0.54%+3.24%+28.88% 14.08B
+2.35%+3.48%+82.95%+43.41% 13.68B
Average +1.52%+0.75%+72.34%+110.73% 26.89B
Weighted average by Cap. +1.82%+0.04%+102.92%+153.19%

Financials

2026 *2027 *
Net sales 335K 290K 272K 247K 465K 32.07M 472K 3.18M 1.25M 16.07M 1.26M 1.23M 53.45M 396K 342K 321K 292K 550K 37.88M 557K 3.76M 1.47M 18.98M 1.49M 1.46M 63.13M
Net income -115M -99.48M -93.33M -85.01M -160M -11.02B -162M -1.09B -429M -5.52B -433M -423M -18.36B -137M -118M -111M -101M -190M -13.1B -193M -1.3B -510M -6.56B -514M -503M -21.84B
Net Debt -167M -144M -135M -123M -231M -15.92B -234M -1.58B -620M -7.98B -625M -612M -26.54B -231M -199M -187M -170M -320M -22.07B -325M -2.19B -859M -11.06B -867M -848M -36.79B
Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Employees
165
Date Price Change Volume
17/08/26 US$3.220 +0.63% 1,168,261
14/08/26 US$3.200 +3.23% 1,000,183
13/08/26 US$3.100 -4.91% 1,318,924
12/08/26 US$3.260 +2.52% 1,185,900
11/08/26 US$3.180 +6.00% 1,803,759
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
3.220USD
Average target price
12.64USD
Spread / Average Target
+292.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CATX Stock